Spironolactone not reduce primary outcome, did reduce hospitalizations for heart failure Findings from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial, have revealed that adding the medication known as spironolactone (Aldactone) to existing therapy did not significantly reduce the composite time to either death from cardiovascular causes, surviving a cardiac arrest, or hospital¬ization to manage heart failure in patients with heart ...
April 9, 2014 - EurekAlert!
Troubled NHLBI TOPCAT Trial Disappoints Although a significant portion of people with heart failure have preserved ejection fraction, none of the proven heart failure therapies has been shown to be beneficial in this important and growing heart failure subpopulation. Now a new NHLBI-funded study has failed to find a benefit in this group for spironolactone, [...]
April 9, 2014 - Forbes